Dark

Check out our API

VRNA
Verona Pharma plc
stock NASDAQ

Inactive

Oct 6, 2025

106.91USD+0.112%(+0.12)1,871,959

Pre-market

0.00USD-100.000%(-106.79)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

06:06AM EST Verona Pharma Announced Completion of Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD Benzinga

02:00AM EST Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial GlobeNewswire Inc

Jan 5, 2022

02:00AM EST ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 GlobeNewswire Inc

Jan 4, 2022

02:00AM EST Verona Pharma to Present at H.C. Wainwright GlobeNewswire Inc

Dec 16, 2021

02:00AM EST Verona Pharma Reports TQT Study Successfully Demonstrated No GlobeNewswire Inc

Nov 12, 2021

08:53AM EST Canaccord Genuity Maintains Buy on Verona Pharma, Raises Price Target to $23 Benzinga

Nov 9, 2021

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

02:00AM EST Enrollment in ENHANCE-1 48-week subset and ENHANCE-2expected to complete around year-end 2021 GlobeNewswire Inc

Nov 1, 2021

03:00AM EDT Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following investor conferences in November 2021: GlobeNewswire Inc

Oct 26, 2021

02:00AM EDT Verona Pharma to Report Third Quarter 2021 Financial Results and GlobeNewswire Inc

Oct 13, 2021

01:38PM EDT Verona Pharma Earlier Announced Co. Will Present Phase 2 Data With pMDI Ensifentrine In COPD At CHEST 2021 Benzinga

02:00AM EDT Verona Pharma to Present Phase 2 Data with pMDI Ensifentrine in GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 13, 2021

10:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021 Benzinga

07:39AM EDT HC Wainwright & Co. Initiates Coverage On Verona Pharma with Buy Rating, Announces Price Target of $25 Benzinga

Sep 2, 2021

02:00AM EDT Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at GlobeNewswire Inc

Aug 31, 2021

02:00AM EDT Verona Pharma to Present at H.C. Wainwright 23rd Annual Global GlobeNewswire Inc

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

02:00AM EDT Verona Pharma Reports Second Quarter 2021 Financial Results and GlobeNewswire Inc

Aug 2, 2021

04:28PM EDT Varonis Sees Q3 Adj. EPS $0.01-$0.02 vs $0.01 Est., Sales $96M-$98M vs $94.67M Est.; Sees FY21 Adj. EPS $0.03-$0.05 vs $0.02 Est., Sales $375M-$379M vs $370.16M Est. Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 27, 2021

02:00AM EDT Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present at the following virtual investor conferences in August 2021: GlobeNewswire Inc

Jul 22, 2021

02:00AM EDT Verona Pharma to Report Second Quarter 2021 Financial Results and GlobeNewswire Inc

Jun 10, 2021

10:17AM EDT Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Increases to 5% Benzinga

08:13AM EDT The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal Benzinga

07:56AM EDT Verona Pharma And Nuance Pharma Earlier Announced Collaboration To Develop And Commercialize Ensifentrine In Greater China; Verona To Receive $25M Upfront Cash Payment And $15M Equity Interest And Is Eligible For $179M In Milestones Benzinga

02:00AM EDT $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) GlobeNewswire Inc

May 25, 2021

02:00AM EDT Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. GlobeNewswire Inc

May 4, 2021

02:00AM EDT Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data GlobeNewswire Inc

May 3, 2021

10:19AM EDT Canaccord Genuity Maintains Buy on Verona Pharma, Lowers Price Target to $18 Benzinga

Apr 29, 2021

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

02:00AM EDT ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 GlobeNewswire Inc

Apr 27, 2021

02:00AM EDT Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD GlobeNewswire Inc

Apr 23, 2021

07:28AM EDT The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs Benzinga

02:00AM EDT Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine GlobeNewswire Inc

Apr 21, 2021

02:00AM EDT Verona Pharma to Report First Quarter 2021 Financial Results and GlobeNewswire Inc

Mar 16, 2021

07:36AM EDT Verona Pharma Awarded U.S. Patent 10,945,950 'Liquid inhalation formulation comprising RPL554' Benzinga

Mar 2, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director. GlobeNewswire Inc

Mar 1, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021. GlobeNewswire Inc

Feb 25, 2021

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

02:00AM EST Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial GlobeNewswire Inc

Feb 18, 2021

02:00AM EST Verona Pharma to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 2, 2021

12:49PM EST Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study Benzinga

06:17AM EST In a release issued under the same headline earlier today byVerona Pharma plc(Nasdaq: VRNA),please note that all instances of the unit "g" were mistakenly represented as "mg." The corrected release follows: GlobeNewswire Inc

05:11AM EST Verona Pharma's pMDI Ensifentrine Shows Improved Lung Function In Mid-Stage COPD Study Benzinga

02:00AM EST Verona Pharma Reports Positive Phase 2 Results with pMDI GlobeNewswire Inc

Jan 14, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its pilot clinical study evaluating the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (pMDI) formulation in U.S. patients hospitalized with COVID-19. GlobeNewswire Inc

Jan 5, 2021

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting at 8:00 AM ET on Monday, January 11, 2021. GlobeNewswire Inc

Nov 9, 2020

02:00AM EST Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the following virtual investor conferences in November 2020: GlobeNewswire Inc

Oct 29, 2020

03:00AM EDT Verona Pharma plc Operational Update and Financial Results for the GlobeNewswire Inc

Oct 22, 2020

02:00AM EDT Verona Pharma to Announce Interim Results for the Three and Nine GlobeNewswire Inc

Oct 13, 2020

02:00AM EDT Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life GlobeNewswire Inc

Sep 8, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the initiation of a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurized metered-dose inhaler (pMDI) formulation in U.S. patients hospitalized with COVID-19. GlobeNewswire Inc

Sep 2, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on Monday, September 14, 2020 at 5:00 PM ET. GlobeNewswire Inc

Aug 25, 2020

12:58PM EDT Jefferies Assumes Verona Pharma at Buy, Announces Price Target of $17 Benzinga

Aug 24, 2020

02:00AM EDT Verona Pharma to Present Phase 2b data with Ensifentrine in COPD GlobeNewswire Inc

Aug 19, 2020

06:11AM EDT Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD Benzinga

02:00AM EDT Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical GlobeNewswire Inc

Aug 14, 2020

01:30PM EDT Verona Pharma Earlier Reported Q2 EPS $(0.09) Up From $(0.10) YoY Benzinga

01:28PM EDT Verona Pharma Q2 EPS $(0.09) Up From $(0.10) YoY Benzinga

02:00AM EDT Verona Pharma plcOperational Update and Financial GlobeNewswire Inc

Aug 10, 2020

10:25AM EDT Benzinga's Top Upgrades, Downgrades For August 10, 2020 Benzinga

05:32AM EDT Canaccord Genuity Initiates Coverage On Verona Pharma with Buy Rating, Announces Price Target of $17 Benzinga

Aug 3, 2020

02:00AM EDT Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (Verona Pharma), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020: GlobeNewswire Inc

Jul 30, 2020

02:00AM EDT Verona Pharma to Announce Interim Results for the Three and Six GlobeNewswire Inc

Jul 20, 2020

04:45PM EDT 04:45 Monday, July 20, 2020 RTTNews

06:35AM EDT When Trading Is Your Career, Consistency Is The Benchmark Benzinga

05:11AM EDT 80 Biggest Movers From Friday Benzinga

Jul 17, 2020

02:43PM EDT Mid-Afternoon Market Update: Nasdaq Rises 40 Points; NIO Shares Plummet Benzinga

12:00PM EDT Mid-Day Market Update: Dow Falls 50 Points; ALX Oncology Shares Spike Higher Benzinga

10:28AM EDT Verona Pharma Shares Halted On Volatility; Shares Up 125% Benzinga

10:17AM EDT Mid-Morning Market Update: Markets Mostly Flat; Netflix Issues Disappointing Subscriber Guidance Benzinga

09:57AM EDT Shares of clinical-stage biopharmaceutical company focused on respiratory diseases Verona Pharma plc (VRNA) are surging more than 85% friday morning at $8.72 after the company said it has raised approximately $200 million in private placement to fund its phase III study dubbed ENHANCE in chronic obstructive pulmonary disease (COPD). RTTNews

07:16AM EDT Verona Pharma Raises $200M In Oversubscribed Private Placement And Subscription Benzinga

02:00AM EDT THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (MAR). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. GlobeNewswire Inc

Share